Curemark
Quick facts
Phase 3 pipeline
- CM-AT · Neurology / Psychiatry
CM-AT is a serine protease that breaks down extracellular proteins to improve protein digestion and absorption in patients with autism spectrum disorder.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: